The first | Targeted BCMA CAR-T cell therapy was approved for marketing!

544px;text-align:justify;white-space:normal;background-color:#FFFFFF;text-indent:2em;'>

544px;text-align:justify;white-space:normal;background-color:#FFFFFF;text-indent:2em;'> On March 27, 2021, Bristol-Myers Squibb (BMS) and bluebird bio (bluebird bio, Inc) jointly announced that the U.

544px;text-align:justify;white-space:normal;background-color:#FFFFFF;text-indent:2em;'>

544px;text-align:justify;white-space:normal;background-color:#FFFFFF;text-indent:2em;'> It is worth mentioning that this is the world's first CAR-T cell therapy targeting BCMA.

544px;text-align:justify;white-space:normal;background-color:#FFFFFF;text-indent:2em;'>

544px;text-align:justify;white-space:normal;background-color:#FFFFFF;text-indent:2em;'> Unlike the previously approved 4 CAR-T cell therapies, the target of the approved Abecma is BCMA-the first 4 CAR-T therapies target CD19.

544px;text-align:justify;white-space:normal;background-color:#FFFFFF;text-indent:2em;'>

544px;text-align:justify;white-space:normal;background-color:#FFFFFF;text-indent:2em;'> B cell maturation antigen (BCMA), also known as TNFRSF17 or CD269, is a member of the tumor necrosis factor receptor (TNFR) superfamily.

544px;text-align:justify;white-space:normal;background-color:#FFFFFF;text-indent:2em;'>

544px;text-align:justify;white-space:normal;background-color:#FFFFFF;text-indent:2em;'> Compared with other popular targets such as PD-1/PD-L1 and PCSK9, the BCMA targeted therapy under investigation is impressive because it only focuses on multiple myeloma (MM).

544px;text-align:justify;white-space:normal;background-color:#FFFFFF;text-indent:2em;'>

544px;text-align:justify;white-space:normal;background-color:#FFFFFF;text-indent:2em;'> The approval is based on data from the pivotal phase 2 clinical trial KarMMa, which treated 127 patients with relapsed/refractory multiple myeloma who received at least three pre-therapies, including immunomodulators and proteases.

544px;text-align:justify;white-space:normal;background-color:#FFFFFF;text-indent:2em;'>

544px;text-align:justify;white-space:normal;background-color:#FFFFFF;text-indent:2em;'> Among the 100 patients whose efficacy can be evaluated after treatment, the overall response rate (ORR) reached 72%, and 28% of the patients had complete remission.

544px;text-align:justify;white-space:normal;background-color:#FFFFFF;text-indent:2em;'>

544px;text-align:justify;white-space:normal;background-color:#FFFFFF;text-indent:2em;'> In terms of safety, Abecma's overall safety is good.